Compare BW & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | STOK |
|---|---|---|
| Founded | 1867 | 2014 |
| Country | United States | United States |
| Employees | 1650 | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.0B |
| IPO Year | 2015 | 2019 |
| Metric | BW | STOK |
|---|---|---|
| Price | $7.92 | $29.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.00 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 4.9M | 693.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.46 | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,062,388,000.00 | $184,420,000.00 |
| Revenue This Year | $41.58 | N/A |
| Revenue Next Year | $66.70 | $77.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $2.64 | $20.32 |
| 52 Week High | $22.03 | $40.22 |
| Indicator | BW | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 37.86 |
| Support Level | $6.75 | $28.02 |
| Resistance Level | $11.34 | $33.61 |
| Average True Range (ATR) | 0.47 | 1.31 |
| MACD | 0.08 | -0.34 |
| Stochastic Oscillator | 23.51 | 8.70 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.